Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Leicester Geneticists Unearth The Roots Of Human Genetic Variation
A new study at the University of Leicester is using advanced single molecule methods to explore processes that lie at the very core of DNA variation in humans.
generic viagra online
University Of Hawaii At Manoa Professor Co-Authors Article About Weight And Relationships
Dr. Janet D. Latner, an Associate Professor of Psychology at the University of Hawai"i at Manoa, has co-authored an article in the July 2009 edition of the Journal of Sex & Marital Therapy on "Weight Stigma in Existing Relationships."
News of the day
Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD™, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR® (rosuvastatin calcium) and TRILIPIX® (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD™.
Health Insurance

Sorin Group Announces Regulatory Approval And First Implants Of New-Platform FACIL And REPLY Pacemakers In Japan

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced the Ministry of Health, Labor and Welfare (MHLW) approval to market the FACIL™ and REPLY™ families of dual and single chamber rate responsive pacemakers. The FACIL and REPLY families are based on the latest Sorin Group bradycardia platform. The FACIL pacemaker is an 8cc device, with no compromise on longevity. REPLY offers the complete range of therapies in FACIL with the addition of SafeRTM, the first algorithm able to switch between AAI (atrial-based pacing) and DDD (dual chamber pacing) modes. Both pacemaker families offer advanced therapy options for atrial fibrillation (AF) prevention, recommendations for optimal programming of the system, innovative functions to automate implant and follow-up procedures, and functions specifically designed for patient safety. Dr. Kei Tawarahara (Cardiovascular Division of Hamamatsu Redcross Hospital, Tokyo, Japan) implanted the first FACIL pacemaker in Japan on March 1st, 2009. The FACIL pacemaker will leverage the success of the REPLY family, first implanted in Japan, by Dr. Yuji Nakazato, Professor of Cardiology at Juntendo University Hospital. Dr. Nakazato commented: "The 2007 ESC Guidelines on cardiac pacing and the 2008 ACC/AHA/HRS Guidelines for Device-Based Therapy emphasize the importance of reducing unnecessary ventricular pacing. The REPLY pacemaker with SafeR is able to promote the natural rhythm of this patient, reducing ventricular pacing to a very low percentage. The combination of SafeR, automatic features and good longevity all inside an 8cc pacemaker makes this device the most suitable choice for most of my patients." SafeR technology was first introduced in Europe in September 2003 with AAISafeR™, which has been shown to reduce unnecessary ventricular pacing in both Sinus Node Disease and unselected AV Block patients.1 Unnecessary pacing in the right ventricle has been shown to significantly enhance the risk of patients developing heart failure and atrial fibrillation.2 "The REPLY and FACIL families, based on Sorin Group"s latest generation pacing platform, bring the best of our bradycardia technology to the market and offer a complete range of options for the treatment of bradycardia patients in Japan. Thanks to the REPLY and FACIL families, Sorin Group reinforces its commitment to enhance the standard of care through improved therapies and the delivery of innovative technology in Cardiac Rhythm Management", said Stefano Di Lullo, President of Sorin Group Cardiac Rhythm Management Business. The REPLY and FACIL pacemakers will be distributed in JAPAN by Japan Lifeline Co. Ltd. a leading distributor of medical devices based in Tokyo. References (1) Pioger G, Leny G., Nitzsche R; Ripart A. AAIsafeR Limits Ventricular Pacing in Unselected Patients. PACE 2007; 30: S66-S70) (2) Epstein, Andrew E et al. ACC/AHA/HRS Sorin Group


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009